GlassScriptPhysician profile
Lisa C Shah
NPI 1316129893
$1,513.28
in general payments reported to CMS, 2019-2025
26 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $176 · 2021: $132 · 2022: $206 · 2023: $262 · 2024: $205 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.49 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $276.17 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $245.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $198.53 | 2020-2024 | Shingrix, Bexsero, Arexvy |
| Lilly USA, LLC | $115.09 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Supernus Pharmaceuticals, INC. | $105.82 | 2019-2020 | |
| Abbott Laboratories | $77.34 | 2022-2023 | Freestyle Libre 3 |
| Amgen INC. | $57.39 | 2022-2024 | Repatha, Otezla |
| Abbvie INC. | $57.31 | 2023-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.14 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $22.83 | 2023 | Optimizer |
| Daiichi Sankyo INC. | $22.69 | 2024 | Injectafer |
| Aimmune Therapeutics, INC. | $21.00 | 2025 | Zenpep |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20.16 | 2019 | |
| Insightec,INC | $19.78 | 2023 | Exablate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.23 | 2024 | Xifaxan |
| Edwards Lifesciences Corporation | $17.63 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Seqirus USA INC | $15.57 | 2025 | Fluad, Flucelvax |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2022 | |
| Scynexis, INC. | $15.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.21 | 2021 | |
| Inspire Medical Systems, INC. | $13.96 | 2023 | Inspire |
| Phathom Pharmaceuticals, INC. | $13.14 | 2024 | Voquezna |
| Medtronic USA, INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.